CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
CV Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- –
- Dividend yield
- –
CV Sciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | CV Sciences | Industry median |
|---|---|---|
| Market Cap | $2.53M | $166.30M |
| Enterprise Value | $2.28M | $88.19M |
| PS Ratio | 0.20 | 3.65 |
| PB Ratio | 1.61 | 2.03 |
| P/TBV Ratio | 4.96 | 2.29 |
Enterprise value
| Measure | CV Sciences | Industry median |
|---|---|---|
| EV / Sales | 0.18 | 2.51 |
Income (trailing twelve months)
| Measure | CV Sciences | Industry median |
|---|---|---|
| Revenue | $12.74M | $58.34M |
| Gross Profit | $6.26M | $105.94M |
| Operating Income | -$969.00K | -$21.40M |
| Pretax Income | -$2.00M | -$14.34M |
| Net Income | -$2.01M | -$22.46M |
| EBITDA | -$872.00K | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Margins
| Measure | CV Sciences | Industry median |
|---|---|---|
| Gross Margin | 49.1% | 52.9% |
| Operating Margin | -7.60% | -44.0% |
| Pretax Margin | -15.7% | -13.3% |
| Profit Margin | -15.7% | -40.2% |
| EBITDA Margin | -6.84% | -30.2% |
| FCF Margin | -4.10% | -9.27% |
Returns
| Measure | CV Sciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -118.9% | -53.2% |
| Return on Assets (ROA) | -27.7% | -40.9% |
| Return on Invested Capital (ROIC) | -44.1% | -32.4% |
| Return on Capital Employed (ROCE) | -61.4% | -38.1% |
Growth
| Measure | CV Sciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -14.9% | 5.96% |
| Revenue Growth (3Y CAGR) | -5.24% | 2.25% |
| Revenue Growth (5Y CAGR) | -10.8% | 6.48% |
Balance sheet
| Measure | CV Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $266.00K | $61.43M |
| Total Debt | $18.00K | $118.52M |
| Net Cash (Debt) | $248.00K | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $1.57M | $49.09M |
| Book Value Per Share | $0.01 | $1.37 |
| Tangible Book Value | $510.00K | $23.52M |
| Working Capital | -$64.00K | $76.81M |
Financial position
| Measure | CV Sciences | Industry median |
|---|---|---|
| Current Ratio | 0.99 | 3.34 |
| Quick Ratio | 0.12 | 2.44 |
| Debt / Equity | 0.01 | 0.52 |
| Interest Coverage | -2.94 | -6.26 |
Cash flow (trailing twelve months)
| Measure | CV Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$492.00K | -$12.35M |
| Capital Expenditures | -$30.00K | -$1.08M |
| Free Cash Flow | -$522.00K | -$20.22M |
| FCF Per Share | -$0.00 | -$0.42 |
Efficiency
| Measure | CV Sciences | Industry median |
|---|---|---|
| Asset Turnover | 1.76 | 0.39 |
| Inventory Turnover | 1.58 | 2.70 |
| Revenue Per Employee | $289.61K | $404.87K |
| Profits Per Employee | -$45.59K | -$703.34K |
| Employee Count | 44 | 74 |
Dividends and yields
| Measure | CV Sciences | Industry median |
|---|---|---|
| Earnings Yield | -79.3% | -23.3% |
| FCF Yield | -20.6% | -8.72% |
Shares
| Measure | CV Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 225,829,000 | 58,127,000 |
| Shares Change (YoY) | 3.46% | 10.9% |
| Shares Change (QoQ) | 10.2% | 0.54% |
| Float | 199,149,000 | 49,136,700 |
| Shares Held by Insiders | 11.8% | 11.6% |
Taxes
| Measure | CV Sciences | Industry median |
|---|---|---|
| Income Tax | $7.00K | $79.87K |
Scores
| Measure | CV Sciences | Industry median |
|---|---|---|
| Altman Z-Score | -17.43 | -0.22 |
| Piotroski F-Score | 5 | 4 |
| Beneish M-Score | -2.94 | -2.62 |
Calculated by StockData from CV Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.